Tolterodine ( DrugBank: Tolterodine )

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
17	多系統萎縮症	1
53	シェーグレン症候群	1

17. 多系統萎縮症

臨床試験数 : 119 / 薬物数 : 138 - (DrugBank : 44) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 111

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2100046394	2021-06-01	2021-05-15	Research of Pelvic Floor Electrical Stimulation for Defecation and Urination Dysfunction in Patients ...	Research of Pelvic Floor Electrical Stimulation for Defecation and Urination Dysfunction in Patients ...	multiple system atrophy	Experimental group:Drug (tolterodine) combined with electrical stimulation;	Xuanwu Hospital, Capital Medical University	NULL	Recruiting	30	75	Both	Experimental group:50;	N/A	China

臨床試験数 : 305 / 薬物数 : 325 - (DrugBank : 104) / 標的遺伝子数 : 58 - 標的パスウェイ数 : 188

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04909255 (ClinicalTrials.gov)	March 23, 2021	21/4/2021	Beta-3 Agonist and Anti-muscarinic Agent for Sjogren's Syndrome With Overactive Bladder	The Therapeutic Effect of Beta-3 Agonist and Anti-muscarinic Agent on Overactive Bladder Among Sjogr ...	Sjogren's Syndrome;Overactive Bladder Syndrome	Drug: mirabegron;Drug: oxybutynin, tolterodine, solifenacin	China Medical University Hospital	NULL	Recruiting	20 Years	N/A	All	50	Phase 4	Taiwan